Metabolix, Inc. (MBLX) news stock charts
Metabolix, Inc. (MBLX) Investment Summary:
We are a bioscience company that develops and plans to commercialize environmentally sustainable, economically attractive alternatives to petroleum-based plastics, chemicals and energy. Our strategy is to develop technology platforms that integrate advanced biotechnology with current industrial practice and to commercialize these platforms with industry leading strategic partners. Our first platform, which we are commercializing through Telles, a joint venture with Archer Daniels Midland Company, or ADM, is a proprietary, large-scale microbial fermentation system for producing a versatile family of polymers known as polyhydroxyalkanoates, which we have branded under the name Mirelâ„¢. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f13%2f0001047469-08-002672.html#FIS_BUSINESS"www.metabolix.com
Founded in 1992
METABOLIX INC (MBLX:NASDAQ)
LAST $11.81 USD
CHANGE TODAY +0.12 1.03%
VOLUME 175.5K
As of 8:10 PM 03/19/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of METABOLIX INC (MBLX)
|
OPEN
$11.77
|
PREVIOUS CLOSE
$11.69
|
|
|
DAY HIGH
$11.88
|
DAY LOW
$11.55
|
|
|
52 WEEK HIGH
10/16/09 - $13.45
|
52 WEEK LOW
06/15/09 - $6.20
|
|
|
MARKET CAP
313.5M
|
AVERAGE VOLUME 10 D
202.3K
|
|
|
EPS TTM
$-1.62
|
SHARES OUTSTANDING
26.5M
|
|
|
MBLX Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Brazil's 'Organic' Plastics
06/24/2008 12:01 AM ET
I Have Just One Word for You: Bioplastics
06/19/2008 5:00 PM ET
The Greening Of Metabolix
05/07/2007 5:00 AM ET
Creative Destruction—for the Environment
04/02/2007 12:26 PM ET
Key developments for METABOLIX INC (MBLX)
Metabolix, Inc. Reports Cash Flow from Operations for the Fourth Quarter Ended December 31, 2009
03/10/2010
Metabolix, Inc. reported cash flow from operations for the fourth quarter ended December 31, 2009. For the fourth quarter, the company reported net cash used in operating activities of $5.9 million which represents a plant decrease in cash usage from $7.3 million used during the third quarter of 2009 but it has increased over the $3.7 million used during the comparable period of 2008. Net cash used in operating activities reflects the companys activities in sales and marketing development as wells as research and product development. The increase in net cash usage in the fourth quarter of 2009 compared with the fourth quarter of 2008 is primarily due a decrease in cash proceeds.
Metabolix, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2009
03/10/2010
Metabolix, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2009. For the quarter, the company reported net loss of $9,759,000 or $0.39 per basic and diluted share on total revenue of $205,000 against net loss of $8,904,000 or $0.40 per basic and diluted share on total revenue of $399,000 for the same period a year ago. Loss from operations of $9,825,000 compared to $9,342,000 a year ago. The year-over-year decrease in total revenue was attributable to lower revenue recognized from delivery of Mirel(TM) sample product and a decline in government research grant revenues, primarily related to the completion of the Company's Strategic Environmental Research Development Program grant which ended in 2009. For the full year, the company reported net loss of $37,957,000 or $1.62 per basic and diluted share on total revenue of $1,425,000 against net loss of $36,005,000 or $1.58 per basic and diluted share on total revenue of $1,555,000 for the same period a year ago. Loss from operations of $38,729,000 compared to $38,892,000 a year ago. Net cash used in operating activities of $25,759,000 compared to $18,392,000 a year ago. Purchase of property and equipment of $2,017,000 compared to $794,000 a year ago. Net cash used in operating activities reflects the company's activities in sales and marketing development as well as research and product development. The increase in net cash usage is primarily due to a decrease in cash received during the fourth quarter of 2009. Net cash used in operating activities reflects the company's activities in sales and marketing development as well as research and product development. The increase in net cash usage is primarily due to a decrease in cash received during the fourth quarter of 2009. The year-over-year decrease in total revenue was attributable to lower revenue recognized from delivery of Mirel(TM) sample product and a decline in government research grant revenues, primarily related to the completion of the Company's Strategic Environmental Research Development Program grant which ended in 2009.
Metabolix, Inc. to Report Q4, 2009 Results on 03/10/2010
02/19/2010
Metabolix, Inc. announced that they will report Q4, 2009 results on 03/10/2010
Metabolix, Inc. financial resources
MBLX Competitors
| Company | Last | Change |
| Arkema SA | €27.38 EUR | -0.72 |
| ecoSolutions International | $0.0030 USD | 0.00 |
| Kaneka Corp | ¥593.00 JPY | +10.00 |
| PERF Go-Green Holdings Inc | $0.06 USD | 0.00 |
| Stanelco PLC | 0.37 GBp | +0.03 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | MBLX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 205.0x |
|
| Price/Book | 5.3x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 155.3x |
|
|
MBLX |
||
|
MBLX transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About Metabolix, Inc.
Metabolix Reports Fourth Quarter and Full Year Financial Results and Provides Business Update
2010-03-12 04:41:43
Quote: For the full year, selling, general andadministrative expenses were $15.7 million compared to $15.8 million in2008.BUSINESS UPDATERichard Eno, CEO of Metabolix, stated, “We are very pleased to reportthat the manufacturing of Mirel bioplastic has begun at the Clintonfacility and that we anticipate initial commercial deliveries tocustomers within the next month. We continue to see significant demandfor Mirel and are shifting our focus towards the ramp up of sales, theimplementation of next g...Read article
Metabolix Reports Fourth Quarter and Full Year Financial Results and Provides Business Update
2010-03-11 07:50:50
Quote: For the full year, selling, general andadministrative expenses were $15.7 million compared to $15.8 million in2008.BUSINESS UPDATERichard Eno, CEO of Metabolix, stated, “We are very pleased to reportthat the manufacturing of Mirel bioplastic has begun at the Clintonfacility and that we anticipate initial commercial deliveries tocustomers within the next month. We continue to see significant demandfor Mirel and are shifting our focus towards the ramp up of sales, theimplementation of next g...Read article
Metabolix, Inc. Q4 2009 Earnings Call Transcript
2010-03-11 07:50:49
Quote: Metabolix, Inc. (MBLX)
Q4 2009 Earnings Call
March 10, 2010 4:30 pm ET
Executives
James Palczynski – IR, ICR
Richard Eno – President and CEO
Joseph Hill – CFO
Oliver Peoples – Co-founder, Chief Scientific Officer and VP, Research
Analysts
Michael Cox – Piper Jaffray
Amanda Sigouin – Jefferies
Scott Reynolds – Thomas Weisel Partners
JinMing Liu – Ardour Capital
Ian Horowitz – Rafferty Capital Markets
Pamela Bassett – Cantor Fit...Read article
METABOLIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
2010-03-11 07:50:49
Quote: METABOLIX, INC.Request a Trial to NEW EDGAR Online Pro
Form
8-K for
METABOLIX, INC.
10-Mar-2010Results of Operations and Financial Condition, Financial Statements and Exhibits
Privacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liable...Read article
Metabolix to Conduct a Webcast of Its Fourth Quarter 2009 Earnings Call
2010-03-02 02:54:25
Quote: In addition, the webcast will be archived on theCompany’s website in the investor relations section.About MetabolixFounded in 1992, Metabolix, Inc. is an innovation-driven biosciencecompany focused on providing sustainable solutions for the world’s needsfor plastics, chemicals and energy. The Company is taking a systemsapproach, from gene to end product, integrating sophisticatedbiotechnology with advanced industrial practice. Metabolix is nowdeveloping and commercializing Mirelââ...Read article
Metabolix to Conduct a Webcast of Its Fourth Quarter 2009 Earnings Call
2010-02-22 02:24:18
Quote: In addition, the webcast will be archived on theCompany’s website in the investor relations section.About MetabolixFounded in 1992, Metabolix, Inc. is an innovation-driven biosciencecompany focused on providing sustainable solutions for the world’s needsfor plastics, chemicals and energy. The Company is taking a systemsapproach, from gene to end product, integrating sophisticatedbiotechnology with advanced industrial practice. Metabolix is nowdeveloping and commercializing Mirelââ...Read article
METABOLIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
2010-02-15 05:07:28
Quote: METABOLIX, INC.Request a Trial to NEW EDGAR Online Pro
Form
8-K for
METABOLIX, INC.
29-Jul-2009Results of Operations and Financial Condition, Financial Statements and Exhibits
Privacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liable...Read article
METABOLIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
2010-02-10 03:48:16
Quote: METABOLIX, INC.Request a Trial to NEW EDGAR Online Pro
Form
8-K for
METABOLIX, INC.
29-Oct-2009Results of Operations and Financial Condition, Financial Statements and Exhibits
Privacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liable...Read article
Metabolix Prices Common Stock Offering
2010-01-13 02:19:40
Quote: The gross proceeds to Metabolix, before underwritingdiscounts and commissions and other offering expenses, from the sale ofthe shares are expected to be approximately $27 million. Jefferies &Company and Thomas Weisel Partners LLC are the underwriters for thisoffering. The Company has granted the underwriters a 30-day option topurchase up to 450,000 additional shares to cover over-allotments, ifany. If the underwriters exercise their over-allotment option in full,gross proceeds from the offering,...Read article
Metabolix Announces Commencement of Public Offering of Common Stock
2010-01-13 02:19:40
Quote: TheCompany intends to use the net proceeds it receives from the offeringfor working capital and other general corporate purposes.http://www.sec.gov.Copies of the prospectus supplement relating to these securities may beobtained from Jefferies & Company, Inc., 520 Madison Avenue, New York,NY 10022, 1-888-449-2342 or Thomas Weisel Partners LLC, One MontgomeryStreet, San Francisco, CA 94104, 1-415-364-2720.This press release shall not constitute an offer to sell or thesolicitation of an offer to bu...Read article
World Economic Forum Selects Metabolix as a 2010 Technology Pioneer
2010-01-13 02:19:39
Quote: Comolli, ManagingGeneral Partner, Accel Partners, and a Technology Pioneer SelectionCommittee Member.About MetabolixFounded in 1992, Metabolix, Inc. is an innovation-driven biosciencecompany focused on providing sustainable solutions for the world’s needsfor plastics, chemicals and energy. The Company is taking a systemsapproach, from gene to end product, integrating sophisticatedbiotechnology with advanced industrial practice. Metabolix is nowdeveloping and commercializing Mirel™, ...Read article
Metabolix Announces Completion of Common Stock Offering
2010-01-13 02:19:39
Quote: Copies of the final prospectus supplement and accompanyingprospectus relating to these securities may be obtained from Jefferies &Company, Inc., 520 Madison Avenue, New York, NY 10022, 1-888-449-2342 orThomas Weisel Partners LLC, One Montgomery Street, San Francisco,California 94104 (415) 364-2720.This press release shall not constitute an offer to sell or thesolicitation of an offer to buy, nor shall there be any sale of thesesecurities in any state or jurisdiction in which such offer,solicitat...Read article
World Economic Forum Selects Metabolix as a 2010 Technology Pioneer
2009-12-04 01:15:40
Quote: Comolli, ManagingGeneral Partner, Accel Partners, and a Technology Pioneer SelectionCommittee Member.About MetabolixFounded in 1992, Metabolix, Inc. is an innovation-driven biosciencecompany focused on providing sustainable solutions for the world’s needsfor plastics, chemicals and energy. The Company is taking a systemsapproach, from gene to end product, integrating sophisticatedbiotechnology with advanced industrial practice. Metabolix is nowdeveloping and commercializing Mirel™, ...Read article
Metabolix, Inc., Q3 2009 Earnings Call Transcript
2009-11-27 23:10:06
Quote: Metabolix, Inc., (MBLX)
Q3 2009 Earnings Call
October 29, 2009 4:30 pm ET
Executives
[Laurie Shupe] - Investor Relations
Richard P. Eno - President, Chief Executive Officer, Director
Joseph D. Hill - Chief Financial Officer, Treasurer
Oliver Peoples - Co-founder and Chief Scientific Officer
Analysts
Michael Cox - Piper Jaffray
Laurence Alexander - Jefferies & Company, Inc.
Jeff Osborne - Thomas Weisel Partners
Pamela Bassett - Cantor Fitzgerald
JinMing Liu - Ardour Capital
Presentation
O...Read article
Metabolix Announces Commencement of Public Offering of Common Stock
2009-11-27 23:10:05
Quote: TheCompany intends to use the net proceeds it receives from the offeringfor working capital and other general corporate purposes.http://www.sec.gov.Copies of the prospectus supplement relating to these securities may beobtained from Jefferies & Company, Inc., 520 Madison Avenue, New York,NY 10022, 1-888-449-2342 or Thomas Weisel Partners LLC, One MontgomeryStreet, San Francisco, CA 94104, 1-415-364-2720.This press release shall not constitute an offer to sell or thesolicitation of an offer to bu...Read article
Metabolix Prices Common Stock Offering
2009-11-27 23:10:04
Quote: The gross proceeds to Metabolix, before underwritingdiscounts and commissions and other offering expenses, from the sale ofthe shares are expected to be approximately $27 million. Jefferies &Company and Thomas Weisel Partners LLC are the underwriters for thisoffering. The Company has granted the underwriters a 30-day option topurchase up to 450,000 additional shares to cover over-allotments, ifany. If the underwriters exercise their over-allotment option in full,gross proceeds from the offering,...Read article
Metabolix Announces Completion of Common Stock Offering
2009-11-27 23:10:02
Quote: Copies of the final prospectus supplement and accompanyingprospectus relating to these securities may be obtained from Jefferies &Company, Inc., 520 Madison Avenue, New York, NY 10022, 1-888-449-2342 orThomas Weisel Partners LLC, One Montgomery Street, San Francisco,California 94104 (415) 364-2720.This press release shall not constitute an offer to sell or thesolicitation of an offer to buy, nor shall there be any sale of thesesecurities in any state or jurisdiction in which such offer,solicitat...Read article
METABOLIX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial S
2009-11-27 23:10:02
Quote: Item 1.01Entry into a Material Definitive Agreement.
On November 11, 2009, Metabolix, Inc. (the "Company") entered into an
Underwriting Agreement with Jefferies & Company, Inc. and Thomas Weisel Partners
LLC (the "Underwriting Agreement"), pursuant to which the Company agreed to
offer and sell 3,000,000 shares of its common stock in an underwritten public
offering at a public offering price of $9.00 per share.Pursuant to the terms
of the Underwriting Agreement, the Compa...Read article
Would you like to leave a comment about Metabolix, Inc. MBLX
Find out what social network information about Metabolix, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Metabolix, Inc.'s Stock there is more great penny stock and market information at Realpennies